Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales, net | $176,243 | $127,785 | $336,125 | $239,370 |
| Operating expenses: | ||||
| Cost of sales | 30,348 | 23,421 | 59,153 | 46,439 |
| Research and development | 90,528 | 46,067 | 188,438 | 87,111 |
| Acquired in-process research and development | 16,435 | — | 742,737 | 5,000 |
| Selling, general and administrative | 81,469 | 63,286 | 177,799 | 120,992 |
| Total operating expenses | 218,780 | 132,774 | 1,168,127 | 259,542 |
| Loss from operations | (42,537) | (4,989) | (832,002) | (20,172) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s R&D?
- Mirum Pharmaceuticals, Inc. (MIRM) reported R&D of $90.53M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s R&D increased by 96.5% year-over-year, from $46.07M to $90.53M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s R&D has grown at a 8.4% compound annual growth rate (CAGR), from $131.43M to $181.18M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Mirum Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude